Ö ÖZ ZE ET T A Am ma aç ç: : Hu man papillomavirus (HPV) ser vi kal kan ser ile iliş ki si gös te ril miş ma jör et yo lo jik ajan dır. Ser vi kal kan ser tüm dün ya da ka dın lar ara sın da en yay gın ikin ci kan ser dir. Bu ça lış ma da Çu-ku ro va Üni ver si te si Tıp Fa kül te si Has ta ne si ne baş vu ran ka dın lar da hu man papillomavirus enfeksiyonu nun pre va lan sı nın araş tı rıl ma sı amaç lan mış tır. G Ge e r re eç ç v ve e Y Yö ön n t te em m l le er r: : Top lam 460 ser vi kal si to lo ji ör ne ği 20-68 yaş ara sı ka dın lar dan top lan mış tır. HPV DNA tes pi ti için MY09/11 ve GP5+/6+ pri mer le ri ile ya pı lan kon sen sus PCR (poly me ra se cha in re ac ti on) tes ti kul la nıl mış tır. HPV DNA pozi tif ör nek ler HPVpU-1M/pU-2R ve HPVpU-31B/pU-2R pri mer le ri ile sı ra sıy la yük sek risk li (HR; high risk) ve dü şük risk li (LR; low risk) tip ler ola rak iden ti fi ye edil miş tir. Ay rı ca HPV DNA po zitif bu lu nan ör nek ler ser vi kal kan ser de en yay gın gö rü len HR HPV tip le ri olan HPV 16, 18, 31 ve 45 için tip spe si fik PCR ile ge no tip len di ril miş tir. B Bu ul l g gu u l la ar r: : Top lam 460 ör nek ten 24 (%5.2)'ü HPV DNA için po zi tif bu lun muş tur. HPV DNA po zi tif 24 ka dın dan 14'ün de (%3) tek ve ya mul tip le enfeksiyon şek lin de HR HPV ti pi ve 10'un da (%2.2) ise tek ba şı na LR HPV po zi tif li ği tes pit edil miş -tir. HPV DNA po zi tif 30 yaş ve üs tü olan 24 ka dın da %33.3 ora nı ile en sık gö rü len HR HPV ti pi HPV tip 16 olup bu nu sı ra sıy la HPV 45 (%20.8), HPV 18 (%4.2) ve HPV 31 (%4.2) iz le miş tir. S So o n nu uç ç: : Çu ku ro va Üni ver si te si Tıp Fa kül te si Has ta ne sine baş vu ran ka dın lar da ge ni tal HPV enfeksiyon pre va lan sı %5.2 bu lun muş tur. HPV enfeksiyonu nun epi de mi yo lo jik araş tır ma la rı nın ser vi kal kan ser ta ra ma stra te ji le ri nin ge liş ti ril me si ve HPV aşı la rı nın uy gun lu ğu nun gös te ril me si için ge lecek te de sür dü rül me si öne ril mek te dir.A An na ah h t ta ar r K Ke e l li i m me e l le er r: : İnsan papillomavirusü 16; in san papillomavirusü 18; po li me raz zin cir re ak si yo nu; ute rin ser vi kal tü mör ler; pre va lans A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : Hu man pa pil lo ma virüs (HPV) is the ma jor eti o lo gic agent for cer vi cal cancer. Cer vi cal can cer is the se cond most pre va lent can cer among wo men in the world. In this study, we ai med to in ves ti ga te the pre va len ce of HPV in fec ti on among wo men ad mit ted to Hos pi tal of Çu -ku ro va Uni ver sity Fa culty of Me di ci ne. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : A to tal num ber of 460 cer vi cal smears we re ob ta i ned from wo men aged bet we en 20-68 ye ars. Con sen sus poly me ra se cha in re ac ti on (PCR) as say using MY09/11 and GP5 + /6 + pri mers we re used to de tect HPV DNA. HPV DNA po si ti ve samp les we re furt her stra ti fi ed as high risk (HR) and low risk (LR) by using HPVpU-1M/pU-2R and HPVpU-31B/pU-2R pri mers, res pec ti vely. HPV DNA po ...
We examined 41 Turkish children with haemophilia for evidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections using the enzyme-linked immunosorbent assay (ELISA). Hepatitis B surface antigen was found to be positive in 11 patients (26.8%) and HCV-specific antibody (anti-HCV) was detected in 10 (24.4%) patients. There was a close relationship of the number of transfusions of blood plasma to the presence of HCV specific antibody, but not to the serum markers of HBV infection. In countries where HBV infection is commonly seen and problems in transfusion practice continue, as in Turkey, children with haemophilia are at greater risk for HBV and HCV infections.
This study was aimed to evaluate the seroprevalence of parvovirus B19 in patients with fibromyalgia syndrome (FS). Seventy-five patients with FS (44.3 +/- 8.3) and 75 healthy controls (44.2 +/- 8.1) were evaluated. Serum anti-B19 IgM and IgG antibodies were measured by ELISA technique. Patients were questioned about duration of symptoms, characteristic features of FS, and symptoms related with viral infection preceding the onset of FS. No significant difference was found regarding the prevalence of anti-B19 IgM antibodies between the groups (p = 0.494). Seropositivity of anti-B19 IgG of the patients was significantly higher than control group (81.3% vs. 64% respectively, p = 0.027). No statistically significant differences were found regarding to the clinical features between fibromyalgia patients with IgG antibody compared to those without IgG antibody. Parvovirus B19 IgG seropositivity was found to be significantly higher in patients with FS. Parvovirus B19 infection might have a role in the etiopathogenesis of FS or might act as a triggering factor.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.